ArticleOncology letters2026
Analysis of DNA methylation markers for diagnosing cervical precancer and cancer: A single-center cross-sectional study.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methylation biomarkers of six tumor suppressor genes (astrotactin 1, distal-less homeobox 1, integrin subunit α 4, relaxin family peptide receptor 3, SOX17 and zinc finger protein 671) were evaluated for their diagnostic efficacy in identifying cervical precancerous lesions and cervical cancer (CC). A total of 283 cases were selected from the General Hospital of Ningxia Medical University (Yinchuan, China) between September 2023 and November 2024. Based on histopathologic diagnoses, patients were divided into four groups: The control group, intraepithelial lesions (LSIL) group, high-grade squamous intraepithelial lesions (HSIL) group and CC group. DNA methylation detection, human papillomavirus (HPV) analysis and cytology analysis were performed. The diagnostic value of DNA methylation detection for CC was assessed by calculating the positive methylation rate, sensitivity, specificity, area under the curve (AUC) and other efficacy indicators. The positive methylation rates and methylation scores of DNA methylation in the HSIL and CC groups were significantly higher compared with those in the control and LSIL groups. Combined DNA methylation detection demonstrated the highest diagnostic efficacy for HSIL and CC, with an AUC value of 0.84, a Youden index of 0.69 and a sensitivity and specificity of 82.0 and 87.0%, respectively. In addition, the diagnostic performance of combined detection was significantly higher compared with that of HPV testing and liquid-based cytology testing (P<0.05). In addition, the diagnostic efficacy of ZNF671 was significantly higher compared with that of the other five methylation markers, with an AUC value of 0.87, a Youden index of 0.73 and a sensitivity and specificity of 78.0 and 95.0%, respectively. Overall, multiple gene site DNA methylation detection was found to be a valuable diagnostic method for CC and may have potential applications in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.